KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells

BACKGROUND: We previously described a sub-population of epithelial ovarian cancer (EOC) cells with a functional TLR-4/MyD88/NF-κB pathway (Type I EOC cells), which confers the capacity to respond to Paclitaxel, a known TLR-4 ligand, by enhancing NF-κB activity and upregulating cytokine secretion – e...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kim, Ki Hyung, Xie, Yanhua, Tytler, Ewan M, Woessner, Richard, Mor, Gil, Alvero, Ayesha B
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2009
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2719595/
https://ncbi.nlm.nih.gov/pubmed/19619321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-7-63
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados